Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504160 | 0.89 | HMGCR (0.35) | ALOX5PTGS2PPARAELANE | |
| SCHEMBL4073818 | 0.87 | TAAR1 (0.35) | ALOX5PTGS2 | |
| SCHEMBL4450766 | 0.85 | ALOX5 (0.38) | ALOX5PTGS2PPARALIPGCYP3A4 | |
| SCHEMBL8200917 | 0.84 | LIPG (0.35) | ALOX5PTGS2PPARALIPGCYP3A4 | |
| SCHEMBL455800 | 0.81 | GABRA1 (0.37) | CYP2D6 | |
| SCHEMBL983439 | 0.80 | LTA4H (0.45) | LIPGCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3363963 | 0.80 | TAAR1 (0.52) | — | |
| SCHEMBL6048335 | 0.80 | LIPG (0.43) | ALOX5PTGS2PPARALIPGELANE | |
| SCHEMBL5207891 | 0.79 | TAAR1 (0.30) | — | |
| SCHEMBL10659939 | 0.78 | LIPG (0.44) | ALOX5PTGS2PPARALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF (DE) | 2012-01-12 | — | — | US | claimed |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | US | claimed |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF | 2011-06-30 | — | — | US | claimed |
| EP-2338488-A1 | Drug combinations with substituted diaryl ureas for the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| EP-2293792-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-1948176-B1 | DIARYL UREAS FOR TREATING PULMONARY HYPERTENSION | BAYER SCHERING PHARMA AG (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009156089-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | claimed |
| US-20090306020-A1 | Combination therapy comprising diaryl ureas for treating diseases | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090227637-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| EP-2094268-A2 | DRUG COMBINATIONS WITH SUBSTITUTED DIARYL UREAS FOR THE TREATMENT OF CANCER | Bayer HealthCare, LLC (US) | 2009-09-02 | — | — | EP | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| JP-2001501910-A | — | — | 2001-02-13 | — | — | JP | claimed |
| EP-1021388-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 2000-07-26 | — | — | EP | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
| WO-1997034853-A1 | PHOSPHORYLATION PROCESS AND CATALYST | PERSTORP AB (SE) | 1997-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306020-A1 | Combination therapy comprising diaryl ureas for treating diseases | CDK6, UBA6, CHUK | ALOX5 4012/4885PTGS2 2290/4885PPARA 4225/4885 |
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | ALOX5 4382/4885PTGS2 3892/4885PPARA 4392/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | ALOX5 420/4885PTGS2 1698/4885PPARA 1023/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | ALOX5 290/4885PTGS2 1954/4885PPARA 1059/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | ALOX5 255/4885PTGS2 1563/4885PPARA 595/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | ALOX5 255/4885PTGS2 1563/4885PPARA 595/4885 |
| US-20090227637-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | ALOX5 4382/4885PTGS2 3892/4885PPARA 4392/4885 |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | UBA6, UBQLN1, UHRF1 | ALOX5 2825/4885PTGS2 1439/4885PPARA 4038/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | ALOX5 439/4885PTGS2 1549/4885PPARA 1395/4885 |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | ALOX5 4382/4885PTGS2 3892/4885PPARA 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.